Calls for papers
-
Copley Scientific, which recently made multiple updates to its range of OINDP testing equipment, has announced the launch of a new range of accessories for testing nasal sprays, including metered dose and dry powder nasal… Read more . . .
-
After having to make a last-minute switch to an online format in 2020, the organizers of the annual Respiratory Drug Delivery (RDD meeting) had more time to plan a virtual meeting for 2021, and they… Read more . . .
-
The US Patent and Trademark Office has issued US Patent No. 10,933,204, titled “Prescription bottle cap capable of administering opioid overdose reversal agent” to CounterAct for its naloxone nasal spray cap, the company said. CounterAct… Read more . . .
-
DPI developer Iconovo announced that it has received its first patent in India covering the company’s ICOone single dose DPI. According to the company, the ICOone platform is already covered by patents in Europe, and patents… Read more . . .
-
Neurelis announced that it has raised $114 million in a Series D preferred stock financing to fund commercialization of Valtoco diazepam nasal spray, which was approved by the FDA for the treatment of seizure clusters or acute repetitive… Read more . . .
-
TFF Pharmaceuticals has announced agreements for feasibility studies with vaccine developer GreenLight Biosciences and with NeuroRx. TFF is performing studies to determine if dry powder formulations of GreenLight’s mRNA COVID-19 vaccine candidate and NeuroRx’s Zyesami… Read more . . .
-
Inhalation CDMO Vectura has announced the addition of a new dry powder inhaler filling and assembly line at its facility in Chippenham, UK that will increase the company’s DPI manufacturing capability to up to 1… Read more . . .
-
The Lundquist Institute for Biomedical Innovation (TLI, formerly LABioMed) has licensed a dry powder synthetic lung surfactant formulation to The Bill & Melinda Gates Medical Research Institute (Gates MRI), TLI said. Gates MRI plans to develop… Read more . . .
-
AIM ImmunoTech announced that that the first subjects have been dosed in a Phase 1 safety study of an intranasal formulation of the company’s Ampligen rintatolimod, which the company is developing for the prevention and/or… Read more . . .
-
According to Pneumagen, its Neumifil carbohydrate binding module (mCBM), which it is developing as a nasal spray for the prevention and treatment of respiratory infections, significantly reduced symptoms and weight loss in a hamster model… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA